Vulvar dysplasia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:59:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Vulvar dysplasia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Pembrolizumab for Patients with High-Grade HPV-Related Vulvar and Cervical Lesions https://clinicaltrials.eu/trial/study-on-pembrolizumab-for-patients-with-high-grade-hpv-related-vulvar-and-cervical-lesions/ Wed, 29 Apr 2026 14:57:59 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-for-patients-with-high-grade-hpv-related-vulvar-and-cervical-lesions/ This clinical trial is focused on studying the effects of the medication pembrolizumab, also known by its code name MK-3475, on certain types of lesions related to the human papillomavirus (HPV). Specifically, the study is looking at pre-cancerous high-grade lesions found in the vulva and cervix, which are areas of the female reproductive system. These lesions are known as cervical high-grade squamous intraepithelial lesions (HSIL) and vulvar intraepithelial neoplasia (VIN) 2-3. The purpose of the study is to determine how effective pembrolizumab is in causing these lesions to completely regress, meaning they disappear or reduce significantly.

Participants in the study will receive pembrolizumab through an intravenous infusion, which means the medication is given directly into a vein. The study will follow a single-arm design, meaning all participants will receive the same treatment without a comparison group. The treatment period is expected to last up to six months. Throughout the study, participants will be monitored for changes in their lesions and any side effects they may experience. The study aims to see if pembrolizumab can help reduce or eliminate the lesions and prevent them from progressing to more serious conditions like cancer.

The study will also track the presence of HPV in participants and assess whether the virus is still detectable after treatment. By the end of the study, researchers hope to gather valuable information on the potential benefits of pembrolizumab for treating these specific HPV-related lesions. This could lead to new treatment options for individuals with similar conditions in the future.

]]>